4 Health Care Stock Stories Ready for Monday Perusal
Sanofi-Aventis (NYSE:SNY): Closing price $50.56
ImmunoGen on Monday announced the presentation of interim data from the ongoing Phase I trial of Sanofi’s SAR566658 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting (abstract #A73) being held in Boston. SAR566658 is an ADC targeted to CA6, which is found on many cases of ovarian, breast, and other epithelial cancers. The data indicate that SAR566658 is generally well-tolerated and can induce objective responses and sustained stable disease in heavily pretreated patients who have CA6-positive cancers.